RCRC
15.10.2019 16:51:08 CEST | Business Wire | Press release
The Royal Commission for Riyadh City (RCRC), formally known as Riyadh Development Authority, has invited international experts to participate in a Symposium setting out the next chapter in Riyadh’s development as a sustainable city, one that will enhance the lives of its citizens, while finding solutions to the difficult challenges facing all cities across the world today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005797/en/
‘Riyadh’s Sustainable Future’ Symposium will take place on November 12 & 13, 2019 in Riyadh and will focus on four of the capital’s most ambitious projects, launched by King Salman bin Abdulaziz Al Saud, and stemming from an initiative from Prince Mohammed bin Salman bin Abdulaziz Al Saud, the Crown Prince.
These four projects are transformative and will help to establish Riyadh as one of the most livable cities in the world.
King Salman Park (www.riyadhksp.sa/en/ ) promises to be the largest green city park in the world; Sports Boulevard (www.riyadhalmasar.sa/en/ ) will be a state-of-the-art new health and wellness destination in the heart of the city; Green Riyadh (www.riyadhgreen.sa/en/ ) will focus on planting 7.5 million trees all over the city; and Riyadh Art (www.riyadhart.sa/en/ ) will delight art lovers with its 1,000 curated art pieces, iconic installations and annual arts festival through its world-class interactive public arts program.
The Symposium will invite discussion across a variety of subject areas, including climate change; sustainable urban development; conservation of the natural environment; critical resource management; energy conservation, production and management; legal frameworks and initiatives to support positive change; and transformative social activation.
The four projects complement Saudi Vision 2030’s ‘Quality of Life’ Program and are aligned with the U.N. Sustainable Development Goals, to create sustainable cities and communities, while driving urgent action against climate change.
Professor David Griggs, an expert in sustainable city planning, who will be attending the Symposium, commented: “The challenge of transforming a rapidly growing city in the desert into a sustainable, responsible, and inspiring place to live is enormous. The world’s largest urban parks, 7.5 million trees to green the city, a 135 km sports corridor and more than 1,000 pieces of public art, are just four of the projects that will transform the city. The ‘Riyadh’s Sustainable Future’ Symposium will bring together some of the world’s leading experts to provide their wisdom and advice for these projects and, in doing so, help Riyadh towards a future its citizens and the world can be proud of.”
For Riyadh and its citizens, the ultimate goal is to create a more sustainable city and a thriving, active community in the long term, while acting against climate change concerns. This Symposium is an important step in achieving that goal.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005797/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
